Conference Proceedings

Management of resected stage III/IV melanoma with adjuvant immunotherapy.

Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison Margaret Weppler, Geoffrey David Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Mark Haydon, Matteo S Carlino, Shahneen Kaur Sandhu, Georgina V Long, Alexander M Menzies

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021

DOI: 10.1200/jco.2021.39.15_suppl.9571

Abstract

9571 Background: Adjuvant anti-PD1 therapy reduces the risk of recurrence in resected stage III/IV melanoma and is now standard care. Limited data exist beyond registration trials. We sought to explore the use of adjuvant immunotherapy in routine clinical practice. Methods: Patients (pts) from 11 Australian centres who received adjuvant nivolumab (nivo) for resected stage III/IV melanoma were included in this study. Efficacy, toxicity, surveillance, recurrence characteristics, management and further treatment outcomes were examined. Results: 471 pts received adjuvant nivo between 8/2018 to 3/2020. 318 (68%) were male, median age 64y (range 17-94), 28 (6%) were AJCC v8 IIIA, 194 (41%) IIIB, ..

View full abstract